Industry Insight | Eli Lilly to Acquire Kelonia Therapeutics in $7 Billion Cell Therapy Deal

April 2026 - Eli Lilly and Company has announced plans to acquire biotechnology firm Kelonia Therapeutics in a deal valued at up to $7 billion, highlighting the growing strategic importance of next-generation cell therapy technologies.

Under the agreement, Lilly will pay $3.25 billion upfront, with additional milestone payments tied to clinical development, regulatory approvals, and commercialization that could bring the total transaction value to approximately $7 billion. The acquisition is expected to close in the second half of 2026, pending customary regulatory approvals.

 Photo by Marvin Radke on Unsplash

Kelonia Therapeutics is developing an in vivo gene delivery platform designed to generate chimeric antigen receptor (CAR) T cells directly within the patient’s body. Unlike traditional CAR-T therapies—which require collecting a patient’s immune cells, genetically modifying them in a laboratory, and reinfusing them—the company’s approach aims to engineer immune cells directly in vivo, potentially simplifying manufacturing and treatment logistics.

The company’s lead candidate, KLN-1010, is designed to generate BCMA-targeted CAR-T cells for the treatment of multiple myeloma. If successful, in vivo CAR-T technologies could significantly reduce the complexity and cost associated with current autologous cell therapy manufacturing processes.

Photo by Trnava University on Unsplash

Industry analysts note that while CAR-T therapies have achieved strong clinical outcomes in several hematological cancers, manufacturing scalability remains one of the field’s major challenges. As more programs advance into clinical development, improving production efficiency and simplifying treatment workflows will be critical for expanding patient access.

The planned acquisition underscores the continued investment by large pharmaceutical companies in next-generation immunotherapy platforms, particularly those that could streamline cell therapy manufacturing and enable broader commercialization.

Sources:

Reuters – report on Lilly’s acquisition of Kelonia Therapeutics (April 2026)

The Wall Street Journal – coverage of Lilly’s negotiations to acquire Kelonia Therapeutics.